Image courtesy of Dr Kristen Brennand & Dr Fred H. Gage/ Salk Institute for Biological Studies
Image courtesy of Dr Yichen Shi and Dr Rick Livesey/ Cambridge Stem Cell Institute
Authors: Mohamed Abou-El-Enein, Ahmed Elsanhoury, Petra Reinke.
Article in Cell Stem Cell, Volume 19, Issue 3, 1 September 2016, Pages 293–297. (doi: 10.1016/j.stem.2016.08.012)
While advanced therapy medicinal products offer great clinical promise, most EU-approved products have not achieved satisfactory commercial performance. Here we highlight a number of issues that prevent current products from obtaining commercial success and pitfalls that developers must overcome in future product development.
EMA: Advanced therapy medicines: exploring solutions to foster development and expand patient access in Europe.
Jul 18, 2016
The European Medicines Agency (EMA) published a report from a multi-stakeholder expert meeting held on 27 May 2016 to explore possible ways to foster the development of ATMPs in Europe and expand patients’ access to these new treatments.
To view the press release click here.
To view the PDF click here.
Jun 23, 2016